Acs Med. Chem. Lett.| Protac-Targeted Jak2 Protein Kinase: a New Approach To Cancer Therapy

Recently, St. Jude Children's Research Hospital published its latest patent on JAK2 protein kinase degraders (WO2021/022076), which was summarized and briefly analyzed by Robert B. Kargbo in the journal ACS Medicinal Chemistry Letters, disclosing a series of novel degraders of JAK2 protein kinase The design and synthesis of a series of novel degradation agents of JAK2 protein kinase with promising applications in cancer therapy.

1, Representative molecules

2, Targets and indications

Target: Janus Kinases 2 (JAK2)
Potential indications: Cancer

3, Synthesis pathway

4, Biological activity

About Miele
Miele PharmaTech is a platform company focusing on CRO/CDMO of small molecule drugs. Founded in 2008, the company aims to provide integrated services from drug synthesis, structure optimization, process development, comprehensive quality research, pilot testing to cGMP production for global biopharmaceutical companies, and has established deep strategic partnerships with 100+ biopharmaceutical companies worldwide. Miele is one of the first companies in China to develop R&D services in the field of protein degradation, with 8 technology platforms including the protein degradation drug development platform (ReThinking PROTAC), and has developed hundreds of core fragments of active molecules that can be scaled up to 100 kg.